The global vectorized antibodies for in vivo expression market was valued at USD 1.35 billion in 2024 and is expected to reach USD 2.54 billion by 2032
During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 8.20% primarily driven by the increasing demand and therapeutic potential
This growth is driven by factors such as the rising prevalence of chronic diseases and advancements in gene delivery technologies
2 Views